Merck & Co Inc (MRK)

61.81
0.72 1.15
NYSE : Health Care
Prev Close 62.53
Open 61.81
Day Low/High 61.63 / 62.40
52 Wk Low/High 47.97 / 65.46
Volume 10.15M
Avg Volume 11.37M
Exchange NYSE
Shares Outstanding 2.76B
Market Cap 166.34B
EPS 1.60
P/E Ratio 30.78
Div & Yield 1.88 (3.10%)

Latest News

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Bristol-Myers Squibb, Merck, Synergy Pharmaceuticals: Doug Kass' Views

Doug Kass shares his thoughts on biotech and discusses the shape of things to come.

Merck Announces Settlement And License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation

Merck Announces Settlement And License Agreement Resolving KEYTRUDA® (pembrolizumab) Patent Litigation

Merck (NYSE:MRK), known as MSD outside the United States and Canada), and certain of its affiliates, today announced it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Company and Ono...

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Ready to Trade Bristol-Myers Squibb, Bank of America, CSX? Here's What to Know

Here's how to trade seven of the most active stocks on the market this week.

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Setback for Bristol-Myers on Lung Cancer Treatment Drugs

Bristol-Myers Squibb suffers a setback in immunotherapy treatment for newly diagnosed lung cancer.

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers Squibb, Where Art Thou? Not in First-Line Lung Cancer Immunotherapy, Sadly

Bristol-Myers suffered another setback when the pharma giant said it would not seek accelerated approval for a combination of two immunotherapy drugs as a treatment for newly diagnosed lung cancer.

The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)

The Pain Before the Gains: Cramer's 'Mad Money' Recap (Thursday 1/19/17)

Don't worry about a little selloff, says Jim Cramer. The data and earnings signal an improving economy.

Merck Foundation Grant Expands Project ECHO® In Vietnam And India

Merck Foundation Grant Expands Project ECHO® In Vietnam And India

The Merck Foundation (Foundation) and the Extension for Community Healthcare Outcomes (ECHO) Institute™ at the University of New Mexico Health Sciences Center announced today that the Foundation has provided a grant...

Why Bristol-Myers Squibb May Be a Merger Target Soon

Why Bristol-Myers Squibb May Be a Merger Target Soon

The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.

Amazon, Merck, Freshpet: Jim Cramer's Views

Amazon, Merck, Freshpet: Jim Cramer's Views

Cramer shares his views on the pajama traders, and talks turkey about pet stocks.

Allergan, Schlumberger, IBM: Doug Kass' Views

Allergan, Schlumberger, IBM: Doug Kass' Views

Doug Kass shares his thoughts on animal spirits, and discusses his astonishment at some rising optimism.

Merck Is a 'Risk Worth Taking' in Spite of Trump Comments, Top Trader Claims

Merck Is a 'Risk Worth Taking' in Spite of Trump Comments, Top Trader Claims

Merck has 'all the momentum right now,' Lebenthal Asset Management CEO Jim Lebenthal said.

Jim Cramer -- We Can't Stifle Innovation in Health Care

Jim Cramer -- We Can't Stifle Innovation in Health Care

Rising drugs prices are a concern to Donald Trump but we can't let development of 'wonder drugs' slow in the health care sector, Cramer said.

Why You Should Watch These 6 Stocks Rising on Unusual Volume

Why You Should Watch These 6 Stocks Rising on Unusual Volume

Unusual volume flow could mean a spike in volatility. Here's a technical look at how to trade six stocks, including Smucker's and Merck.

Analysts' Actions -- Bank of America, Merck, Morgan Stanley, Valero and More

Analysts' Actions -- Bank of America, Merck, Morgan Stanley, Valero and More

Here are Thursday's top research calls, including upgrades for Bank of America, Merck and Morgan Stanley, and a downgrade for Valero.

Bristol-Myers and AstraZeneca Take Beatings

Bristol-Myers and AstraZeneca Take Beatings

It happened in the wake of Merck's latest drug approval.

Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session

Nasdaq Posts Another Record Close in Unpredictable Trump-Triggered Trading Session

Like President-elect Donald Trump's first press conference since securing victory, Wall Street's trading on Wednesday was unpredictable.

Stocks Back to Gains in Unsettled Trade After Trump News Conference

Stocks Back to Gains in Unsettled Trade After Trump News Conference

The Nasdaq falls from records in a volatile session following President-elect Donald Trump's first press conference since winning the election.

Cramer: Trump Doesn't Seem to Care About the Trump Rally

Cramer: Trump Doesn't Seem to Care About the Trump Rally

He's never really been a stock market guy anyway.

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

Midday Report: Biotech Stocks Tumble on Trump's Talk; Stocks Fluctuate

U.S. stocks fluctuated Wednesday after President-elect Trump targets the biotech industry in his first press conference since July.

For Merck, Keytruda Is 'Extraordinarily Positive' : More Squawk From Jim Cramer

For Merck, Keytruda Is 'Extraordinarily Positive' : More Squawk From Jim Cramer

Merck's lung cancer treatment will get a speedy review by the FDA, but it 'knows better than to go out and give false hope,' TheStreet's Jim Cramer said.

Why Rite Aid, Ford, Merck Are Wednesday's Most Active Movers

Why Rite Aid, Ford, Merck Are Wednesday's Most Active Movers

Here's a technical look on how to trade seven of today's most active stocks.

Stocks Mostly Lower as Trump Targets Pharma Industry

Stocks Mostly Lower as Trump Targets Pharma Industry

The Nasdaq takes a turn lower on Wednesday as President-elect Donald Trump targets the biotech and pharmaceutical industry in a press conference.

Cramer: What Happened to the Pajama Traders?

Cramer: What Happened to the Pajama Traders?

The terror that the futures struck, rightly or wrongly, has disappeared.

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

Trump Tax Policies Could Make J&J a Bigger Threat in 2017

While there remains many unknowns about the specifics of possible legislation, CEO Alex Gorsky suggested that tax reform and repatriation could be a major game changer for J&J.

4 Biotech Names That Could Be M&A Targets

4 Biotech Names That Could Be M&A Targets

Animal health and oncology deal activity is heating up in 2017.

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

Cramer: How Walmart, Amex, IBM and Nike Could Help the Dow Hit 20,000

These four Dow components (and eight others I'm watching) are nowhere near record highs.